Condition
Episodic Ataxia Type 2
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting1
Withdrawn1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07221292Phase 3Not Yet Recruiting
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT01543750Phase 2WithdrawnPrimary
4-Aminopyridine in Episodic Ataxia Type 2
Showing all 2 trials